HOME >> MEDICINE >> NEWS
Zengen reports positive phase I/II trial results of its peptide molecule for vaginal yeast infection

(May 25, 2004) Zengen Inc. announced today positive phase I/II results for its proprietary molecule CZEN-002 for the treatment of vulvovaginal candidiasis (VVC), commonly known as vaginal yeast infection. The open label, non-randomized study was designed to evaluate the safety, tolerability and pharmacokinetics of CZEN-002 in patients with VVC.

The majority of subjects in the study reported evidence of efficacy as determined by potassium hydroxide (KOH) tests and mycological cultures - 88.2 percent and 87.5 percent, respectively. A total of 20 female patients with VVC were enrolled and treated in the trial, and 17 completed the study. KOH testing and mycological cultures indicated that CZEN-002 is active and that five days of treatment provided positive evidence of anti-infective efficacy. CZEN-002 appeared safe and well-tolerated with no severe adverse reactions. In 100 percent of the plasma samples evaluated, concentrations of CZEN 002 were either not detected or were below the limit of quantitation.

"This trial clearly established the efficacy of CZEN-002," said William Smith, M.D., F.A.C.C., lead study investigator and associate professor, clinical medicine, at Tulane University School of Medicine and Louisiana State University Medical Center. "The encouraging results provide hope that this compound may become a new treatment option for the millions of women diagnosed each year with VVC."

The primary objective of the study was to evaluate the safety and tolerability of vaginally administered CZEN-002. A secondary objective was to assess the systemic absorption of CZEN-002 as determined by the plasma concentrations of the molecule through 21 days following dosing. The CZEN 002 was delivered to the 20 patients in a vaginal gel specifically designed for the purpose of the study.

"This clinical trial marks a major milestone for Zengen," said James M. Lipton, Ph.D., chief scientific officer of Zengen. "Our peptide appears to
'"/>

Contact: Cattaliya Snider
sniderc@ruderfinn.com
310-479-9929
Zengen
25-May-2004


Page: 1 2 3

Related medicine news :

1. Zengens new study reviews novel approach to control inflammation using melanocortin receptors
2. Lead in the environment causes violent crime, reports University of Pittsburgh researcher at AAAS
3. Study reports women dont experience undue pain, anxiety during mammography screening
4. Risks from labor after prior cesarean delivery low, study reports
5. Federal forum reports Americans aging well, but gaps remain
6. Early reports of thrombosis after insertion of drug-eluting stents
7. Study reports genetic susceptibility to alcoholism in NMDA receptor
8. Parents can provide accurate reports of their childrens ADHD symptoms
9. UCI Tobacco research center reports why teens are most vulnerable to smoking addiction
10. MIT reports new insights in visual recognition
11. Study reports improved method to identify fetal DNA in maternal blood samples

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2017)... ... June 24, 2017 , ... The ... the Sheraton Erie Bayfront and Erie Convention Center on June 8-10. The ... a student quiz bowl, award and scholarship presentations, and professional networking. , ...
(Date:6/24/2017)... ... June 24, 2017 , ... Doorknobs are for convenience, deadbolts ... as getting a guard dog or having an alarm system installed. But unless there ... forced entry. Yair Frenkel, owner of TX Premier Locksmith in Killeen, TX says: “In ...
(Date:6/23/2017)... ... , ... By scoring 100% for fiscal management and accountability, the Arthritis National ... evaluator, Charity Navigator, validating ANRF's work as a top charity in America. , This ... and earns ANRF a spot on their “ 10 Charities Worth Watching ” list ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Military Officers Association of America (MOAA) announced ... Veterans Affairs, retired Marine Col. Thomas G. Bowman. , Bowman currently serves as the ... an intimacy with the issues and challenges veterans face with the VA. Following a ...
(Date:6/23/2017)... ... , ... Everybody has their own personal preference when it comes to pornography. ... people don't like it at all. FindaTopDoc took a look at what makes people ... give readers a taste of their deepest, darkest fantasies and has the ability to ...
Breaking Medicine News(10 mins):
(Date:6/14/2017)... Calif. , June 14, 2017 The ... the City of Fremont and ... of the bio-pharma industry in California ... technology, enabling executive networking, and fostering workforce development. The ... development and growth of start-ups, as well as small ...
(Date:6/13/2017)... Ind. , June 13, 2017 Zimmer Biomet ... musculoskeletal healthcare, today announced that the U.S. Food and Drug ... dated June 3, 2015 relating to its Zhejiang, ... "The successful clearance of the ... manufacturing facility is a measure of the progress ...
(Date:6/11/2017)... -- Eli Lilly and Company (NYSE: LLY ) announced ... galcanezumab, an investigational treatment for the prevention of episodic ... secondary endpoints for galcanezumab compared to placebo at both ... and REGAIN) will be presented today at the American ... Boston . "The detailed Phase ...
Breaking Medicine Technology:
Cached News: